Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

SELLAS Life Sciences Delivers Oral Presentation Of SLS009 Phase 1 Data For Acute Myeloid Leukemia Patients At 2024 European School of Haematology Conference

Author: Benzinga Newsdesk | March 01, 2024 09:31am

- All key study objectives regarding pharmacokinetic, pharmacodynamic, safety, and clinical activity were met -

- Complete remission (CR) achieved after three months of treatment with duration of eight months and one year survival at the latest assessment -

- First time achievement of CR with CDK9 inhibition monotherapy in relapsed/refractory (r/r) acute myeloid leukemia (AML) patient –

- Phase 2a data in r/r AML patients expected in March and Q2 2024 -

Posted In: SLS